
|Articles|February 6, 2023
Bristol Myers Squibb Launch New DTC Campaign in Plaque Psoriasis
BMS launched a new direct-to-consumer (DTC) campaign for SOTYKTU™ (deucravacitinib) for the plaque psoriasis community.
Advertisement
The campaign, “Found It,” is part of a robust DTC program designed to educate adults with moderate to severe plaque psoriasis about SOTYKTU™, a new oral treatment option.
The first TV spot, which aired on Sunday, February 5th during the 65th annual Grammy Awards, celebrates the feeling of finally finding a treatment that may restore confidence and freedom and, most importantly, the ability to love your skin.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Bayer Shares Briefly Dip After Activist Investor Offloads Millions of Dollars in Company Stock
2
Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio
3
Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s Ownership of Shionogi-Apnimed Sleep Science
4
FDA Sends Warning Letter to ImmunityBio for Misleading Claims in Advertisement
5




